Hybrid systems of glibenclamide and layered double hydroxides for solubility enhancement for the treatment of diabetes mellitus II

The present research aimed at the synthesis of two new systems containing glibenclamide (GLIB) and double layered hydroxides (LDH). GLIB is an important drug used in the treatment of diabetes mellitus II (DM-II). The choice of zinc LDH (Zn2Al-Cl-GLIB) and magnesium (Mg2Al-Cl-GLIB) was performed with a possible antioxidant action, important for the treatment of DM II. The systems were characterized by x-ray diffractometry, medium infrared spectroscopy, surface area, thermogravimetry and differential exploratory analysis, mass analysis, chemical analyzes of carbon, nitrogen, and hydrogen (CHN) and metals (ICP-OES). The amount of GLIB carried by Mg2Al-Cl-GLIB was 0.625 mMol.g(-1) and 0.666 mMol.g(-1) by Zn2Al-Cl-GLIB. The release was performed by the dissolution test in simulated gastric and intestinal media. In the intestinal simulated medium LDH Zn2Al-Cl-GLIB and Mg2Al-Cl-GLIB showed a 13% and 30% solubility enhancement in relation to the isolated drug (GLIB), respectively. In addition, Zn2Al-Cl-GLIB presented antioxidant activity, suggesting potential action against free radicals produced in the chronic phase of DM-II. For both systems mesopore formation and absence of cellular toxicity were observed in macrophages.